Wise Funds: Biotech bargains offer buying opportunity amid volatile markets

Ageing population underpinning demand

clock • 4 min read
Vincent Ropers of Wise Funds
Image:

Vincent Ropers of Wise Funds

The start of 2022 has been anything but plain sailing for investors, with Russia’s invasion of Ukraine unleashing further volatility on markets already grappling with soaring inflation and rapidly shifting central bank policies.

While heightened geopolitical and macroeconomic uncertainty has naturally led investors to pivot portfolios towards more defensive assets such as commodities, this environment may unearth attractive opportunities in a number of high growth sectors with comparatively strong value prospects.   For discerning investors able to act opportunistically, the healthcare and biotechnology sectors seem particularly compelling. Both spaces appear to have been unjustifiably punished post the Covid-19 rebound, and look particularly attractive both from an absolute and relative valuation standpoint. Mo...

To continue reading this article...

Join Investment Week

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

More on Investment Trusts

Trustpilot